– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus ...

A progressive liver condition affects thousands of Americans, but early symptoms are often dismissed as everyday ailments.

IQIRVO ® (elafibranor) is the first new medicine approved in nearly a decade for the treatment of rare cholestatic liver disease Primary Biliary Cholangitis ... tolerate UDCA. 1 Ipsen Logo ...

IQIRVO ® (elafibranor) is the first new ... of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in ...

Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).

1 Elafibranor, a 'first-in-class' molecule marketed and ... trademark Iqirvo® since June 2024 for the treatment of Primary Biliary Cholangitis (PBC), was developed by GENFIT, from initial ...

Elafibranor, a 'first-in-class' molecule marketed and commercialized in the United States, the European Union and the UK by Ipsen under the trademark Iqirvo® since June 2024 for the treatment of ...

Here’s the kicker: I’m one of 47,583 people in Singapore certified in first aid, including cardiopulmonary ... low at 58 per cent. That is a step up from 2020, when just 50 per cent had ...

At the start of the year, there had been no new therapies for rare cholestatic liver disease primary biliary cholangitis (PBC ... PBC could be worth $1.5 billion or more per year.

Syracuse — The three candidates on the Democratic primary ballot for Syracuse mayor soon will answer questions in the same room, at the same time for the first time this election cycle.

Ukraine's Zelenskiy Says Russian Ceasefire First Step Required for Peace Settlement (Reuters) - Ukrainian President Volodymyr Zelenskiy said on Tuesday that progress in resolving the more than ...

ADNOC’s sukuk debut is set to raise $1. ... the primary debt capital markets issuing and rated entity for ADNOC Group, and it is now accessing sukuk debt from capital markets for the first ...